Aardvark Therapeutics, Inc. (AARD) is a San Diego-based clinical-stage biopharmaceutical company developing oral, gut-restricted small molecules that target bitter taste receptors to suppress hunger. Its lead asset, ARD-101, is in development for hyperphagia in Prader-Willi syndrome. The stock last traded near $1.06, a decline of 7.83% from Tuesday's close of $1.15, and it sits roughly 88% below its level a year ago. No fresh company announcement coincided with the move; the selling is a continuation of the post-earnings drift that has now erased the gains from the early-November rally.
Aardvark reported third-quarter results on November 13: a net loss of $19.2 million, or $0.88 per basic and diluted share, versus a consensus estimate of about $0.75 per share. Research and development expense rose to $15.7 million from $13.7 million a year earlier, and the nine-month net loss widened to $55.2 million from $40.0 million. With no product revenue and cash burn of roughly $50 million over three quarters, the update reminded investors that the next meaningful clinical milestone sits in 2027. That realization has driven five consecutive lower sessions since the stock peaked at $1.59 on November 11.
Sell-side sentiment has deteriorated steadily. Morgan Stanley maintained a Sell rating on the shares on November 13, RBC Capital reiterated Hold with a $2.50 target, and Stifel cut its target to $2 from $6 on November 16, citing difficulties interpreting data from a small, prematurely terminated study. Raymond James and Oppenheimer have both moved to neutral stances in recent weeks. The pattern of target reductions rather than full-blown capitulation keeps a supply of sellers in the market, and a rising short base — roughly 1.04 million shares, or about 8% of float — adds to the downdraft on weak days.
The FDA lifted its clinical hold on ARD-101 in October, but the relief rally faded quickly because the agency has only agreed to an open-label trial at 200 mg twice daily while a broader development plan awaits a meeting in the first quarter of 2027. The Phase 3 HERO trial randomized 67 of 90 planned participants before termination, and management described the efficacy findings as exploratory, observational and inconclusive. Aardvark's second program, ARD-201, remains on hold. Investors must now underwrite a re-designed study, additional spending, and a multi-year timeline before any approval path becomes visible.
No new company-specific catalyst was released Wednesday, so today's leg lower is best read as continued de-risking rather than a reaction to fresh news. The stock is trading far below its 50-day average near $3.60 and its 200-day average near $5.50, and the intraday trend has been one of persistent selling into modest bounces. Volume of roughly 66,000 shares by late morning, against a three-month daily average near 627,000, points to an absence of buyers rather than heavy institutional dumping — a pattern consistent with thin order books in a sub-$25 million market capitalization name that frequently moves by more than 7% in a session.
The decline was not mirrored by the wider tape. The S&P 500 and Nasdaq-100 traded modestly lower, while the SPDR S&P Biotech ETF (XBI) was essentially flat and the iShares Biotechnology ETF (IBB) slipped less than 1%. The divergence confirms an idiosyncratic seller. Technically, the stock has lost the $1.20 area that cushioned November trading and is pressing toward the $0.93 52-week low set in late October, with momentum readings in oversold territory — a setup that can produce sharp but short-lived counter-trend rebounds.
The score runs from 0, meaning no meaningful news and a normal-sized move for the stock, to 100, meaning transformative news plus an extreme, rare price move. Here the score is 16 out of 100. The verified news backdrop — a wider quarterly loss, inconclusive trial data, and a string of target cuts — is only moderately material relative to a company already trading below the value of its $60.3 million cash balance, and none of it was released today. The decline was about 1.1 times this stock's typical absolute daily move, and 16 of the last 60 sessions produced moves of 7.83% or more. Moderate news plus an ordinary-for-this-stock move leaves a low score.
The next hard checkpoint is FDA feedback on the ARD-101 development plan, expected after a first-quarter 2027 meeting, followed by any resumption of PWS clinical activity. Management has said existing cash and investments of $60.3 million should fund operations through 2027, but further dilution is a realistic risk if a new trial design requires additional capital. Investors will also watch for updates on the litigation filed over the February 2025 IPO period and on compliance with Nasdaq's minimum bid requirement, which becomes relevant if shares settle below $1.00. With no revenue and no near-term data readout, sentiment is likely to stay headline-driven and volatile.
Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are showcased in its curated Trending AI Robots section. The bots differ by strategy, timeframe, performance metrics and the specific symbols they trade, letting users compare approaches side by side. For investors navigating volatile small-cap moves like this one, reviewing the current leaderboard can be a practical next step.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The RSI Oscillator for AARD moved into overbought territory on November 17, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for AARD just turned positive on November 10, 2026. Looking at past instances where AARD's MACD turned positive, the stock continued to rise in 16 of 17 cases over the following month. The odds of a continued upward trend are 90%.
Following a +17.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where AARD advanced for three days, in 88 of 102 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
AARD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AARD as a result. In 21 of 25 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AARD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for AARD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.342) is normal, around the industry mean (3.592). P/E Ratio (-0.363) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. AARD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AARD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology